AYTUHealthcare · Drug Manufacturers - Specialty & GenericAYTU Stock Forecast: Aytu Biopharma, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Aytu Biopharma, Inc. hold a median 12-month price target of $7 — +250.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 12 Sept 2026 — in the upper half.
AYTU stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Aytu Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
AYTU stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AYTU, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +250.0% from it.
Of the 16 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 June 2026 | Ascendiant Capital | Maintains | Buy | $14 → $15 |
| 10 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 25 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 25 Sept 2025 | Maxim Group | Maintains | Buy | — |
| 1 July 2025 | Lake Street | Initiates | Buy | — |
| 30 June 2025 | Ascendiant Capital | Initiates | Buy | — |
| 9 Aug 2023 | Maxim Group | Initiates | Buy | — |
| 31 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 July 2022 | HC Wainwright & Co. | Maintains | Buy | $11 → $6.00 |
| 17 May 2022 | Cantor Fitzgerald | Maintains | Overweight | $11 → $5.00 |
| 28 Apr 2022 | HC Wainwright & Co. | Maintains | Buy | $24 → $11 |
| 30 Mar 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
| 25 Nov 2020 | HC Wainwright & Co. | Initiates | Buy | — |
| 25 Nov 2020 | Northland Securities | Initiates | Outperform | — |
| 29 May 2020 | HC Wainwright & Co. | Initiates | Buy | — |
| 22 Oct 2018 | Northland Securities | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AYTU appears on the weeks it earns a place.
AYTU vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Sept 2026, Aytu Biopharma, Inc. returned −15.3% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
AYTU analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Aytu Biopharma, Inc. (AYTU) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.9×
- Price / sales
- 0.4×
- Price / book
- 0.6×
- EV / EBITDA
- −6.7×
Cheaper than 82% of US stocks
Cheaper than 86% of US stocks
Cheaper than 83% of US stocks
Cheaper than 81% of US stocks
- Revenue growth (YoY)
- −32.7%
- Earnings growth (YoY)
- −32.7%
- Gross margin
- 61.2%
- Operating margin
- −32.7%
- Net margin
- −60.2%
Higher than 8% of US stocks
Higher than 15% of US stocks
Higher than 74% of US stocks
Higher than 19% of US stocks
Higher than 9% of US stocks
- Return on equity
- −97.4%
- Return on assets
- −3.7%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 34% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Aytu Biopharma, Inc. (AYTU) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aytu Biopharma, Inc. has a market value of $21.4M and an enterprise value of $17.6M.
Revenue in the twelve months to 31 Mar 2026: $56.6M. The latest quarter shrank 32.7% year on year.
Net income over the same four quarters: −$34.1M, a −60.2% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$1.4M, after $34K of capital spending.
Trailing P/E: −0.9×; forward P/E: −26.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Aytu Biopharma, Inc. employs 82 people — $690K of revenue per employee.
Data provided by Twelve Data
AYTU vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aytu Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about AYTU stock
What is the AYTU stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Aytu Biopharma, Inc. have a median 12-month price target of $7, with estimates ranging from $7 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AYTU stock a buy right now?
Of the 3 analysts covering Aytu Biopharma, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aytu Biopharma, Inc. 65 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AYTU?
As at 12 Sept 2026, Aytu Biopharma, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).
Will AYTU stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +250.0% from the last close, and Ticker Nerd's factor model ranks Aytu Biopharma, Inc. 65 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AYTU stock forecast for 2030?
No analyst covering Aytu Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AYTU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $15 over the next 12 months.
How has AYTU stock performed over the past year?
Aytu Biopharma, Inc. returned -15.3% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Aytu Biopharma, Inc. do?
Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on prescription therapeutics and consumer health products.
About Aytu Biopharma, Inc.
Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on prescription therapeutics and consumer health products. Aytu BioPharma primarily serves patients with complex central nervous system conditions, with products used in the treatment of major depressive disorder and attention deficit-hyperactivity disorder. Its current portfolio also includes medicines for allergic conditions and fluoride-based pediatric supplement products for infants and children. The company markets its prescription products through third-party channels and also offers consumer health items directly to consumers. Based in Denver, Colorado, Aytu BioPharma operates as a commercial-stage healthcare company with a portfolio aimed at addressing ongoing medical needs across psychiatry, pediatrics, and supportive care.
CEO Mr. Joshua R. Disbrow · 82 employees · United States · https://aytubio.com